Epstein Barr Virus Ebv Epidemiology Forecast

DelveInsight’s ‘Epstein–Barr virus (EBV)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Epstein–Barr virus (EBV), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Epstein–Barr virus (EBV) Disease Understanding

Epstein–Barr virus (EBV) is a member of the Herpesviridae family and is a ubiquitous pathogen that is persistently harbored by people throughout the world. EBV is the major cause of infectious mononucleosis and is associated with several malignancies including nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, Burkitt lymphoma, and lymphoma after organ or stem cell transplant.


Primary infection with EBV is more frequent during childhood and causes mild disease. The disease is typically asymptomatic in 20–80% of individuals by the age of 2–3 years. When uninfected teenagers and young adults are exposed to EBV, approximately 30–70% develop infectious mononucleosis (IM) and other EBV associated diseases. There are two types of EBV: type I and type II, also known as Type A and B. These two genotypes were distinguished based on the differences in the EBNA-2 gene. Additionally, Epstein–Barr virus Type I and II can further be subtyped into different EBV strains. The genetic variability between the different EBV strains is thought to occur due to the nature of the EBV life cycle within the lymphocytes. Also, there are many studies in the literature focusing on investigating the genetic variability of the EBV strains trying to correlate this variability to the geographic areas and the disease outcomes. Primary EBV infection or reactivation in the immunocompromised host (particularly those post-hematopoietic stem cell transfer or solid organ transfer) may present as a life-threatening disease characterized by fever, lymphadenopathy, mononucleosis-like syndrome, central nervous system (CNS) disease/myelitis, pneumonia, sepsis-like syndrome, and PTLD.


EBV is an oncogenic virus and continued to attract considerable attention worldwide, primarily due to its oncogenic properties and its association with several human malignancies, including Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC), post-transplant lymphoproliferative disease (PTLD), Hodgkin’s lymphoma (HL) and gastric carcinoma (GC). A detailed understanding of the risk factors or causes of cancer is of paramount importance for any future prevention strategies.

Epstein–Barr virus (EBV) Epidemiology


The Epstein–Barr virus (EBV) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Epstein–Barr virus (EBV) epidemiology segmented as the Total Diagnosed cases of EBV Infectious Mononucleosis, Total Incident cases of EBV+ Cancers, Total Incident cases of EBV+ PTLD. The report includes the scenario of Epstein–Barr virus (EBV) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Epstein–Barr virus (EBV) Epidemiology

The epidemiology segment also provides the Epstein–Barr virus (EBV) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • Total diagnosed cases of EBV+ Infectious mononucleosis in the 7MM were assessed to be 524,537 in 2020; whereas the EBV+ Cancers and PTLD were reported to be 45,341 for the year 2020.
  • As per the estimates, the United States has the highest population of Epstein–Barr virus (EBV). In 2020, the total diagnosed cases of EBV Lymphoma such as the Burkitt lymphoma (BL), Hodgkin lymphoma (HL) is are 1,555 and 9,548 respectively. The EBV-cancer such as Gastric carcinoma (GC) cases were 27,619, and nasopharyngeal carcinoma (NPC) cases were 2,197 for the year 2020.
  • Among the EU5 countries, Among EU5 countries, Germany accounted highest cases of EBV Infectious Mononucleosis i.e., 72,971 in 2020, and EBV+ Cancers and PTLD cases were 4,063.

Scope of the Report

  • Epstein–Barr virus (EBV) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Epstein–Barr virus (EBV) Epidemiology Report and Model provide an overview of the risk factors and global trends of Epstein–Barr virus (EBV) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Epstein–Barr virus (EBV) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Epstein–Barr virus (EBV)
  • The report provides the segmentation of the Epstein–Barr virus (EBV) epidemiology by incident Cases of Epstein–Barr virus (EBV) in 7MM

Report Highlights

  • 11-Year Forecast of Epstein–Barr virus (EBV) epidemiology
  • 7MM Coverage
  • Total Cases of Epstein–Barr virus (EBV)

KOL- Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Epstein–Barr virus (EBV)?
  • What are the key findings of Epstein–Barr virus (EBV) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
  • What would be the total number of patients of Epstein–Barr virus (EBV) across the 7MM during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2017–2030)?
  • What are the disease risk, burden, and unmet needs of Epstein–Barr virus (EBV)?
  • What are the currently available treatments for Epstein–Barr virus (EBV)?

Reasons to buy

The Epstein–Barr virus (EBV) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Epstein–Barr virus (EBV) market
  • Quantify patient populations in the global Epstein–Barr virus (EBV) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Epstein–Barr virus (EBV) therapeutics in each of the markets covered
  • Understand the magnitude of Epstein–Barr virus (EBV) population by its incident cases
  • Understand the magnitude of Epstein–Barr virus (EBV) population by its Etiology-specific cases
  • The Epstein–Barr virus (EBV) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Epstein–Barr virus (EBV) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Epstein–Barr Virus: Market Overview at a Glance

2.1. Market Share (%) Distribution of EBV in 2017

2.2. Market Share (%) Distribution of EBV in 2030

3. Organizations

4. Executive Summary

5. Disease Overview: Epstein–Barr Virus (EBV)

5.1. Introduction

5.2. Classification

5.3. Signs and Symptoms

5.4. Etiology

5.5. Pathogenesis

5.6. EBV Associated Diseases

5.7. Diagnosis

5.7.1. Differential Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM

6.3. Total Incident Population of EBV+ Cancers and PTLD in 7MM

7. 7MM Epidemiology of EBV

7.1. Assumptions and Rationale

7.2. The United States

7.2.1. Total Diagnosed cases of EBV Infectious Mononucleosis in the US

7.2.2. Total Incident cases of EBV+ Cancers in the US

7.2.3. Total Incident cases of EBV+ PTLD in the US

7.3. Germany

7.3.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Germany

7.3.2. Total Incident cases of EBV+ Cancers in Germany

7.3.3. Total Incident cases of EBV+ PTLD in Germany

7.4. France

7.4.1. Total Diagnosed cases of EBV Infectious Mononucleosis in France

7.4.2. Total Incident cases of EBV+ Cancers in France

7.4.3. Total Incident cases of EBV+ PTLD in France

7.5. Italy

7.5.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Italy

7.5.2. Total Incident cases of EBV+ Cancers in Italy

7.5.3. Total Incident cases of EBV+ PTLD in Italy

7.6. Spain

7.6.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Spain

7.6.2. Total Incident cases of EBV+ Cancers in Spain

7.6.3. Total Incident cases of EBV+ PTLD in Spain

7.7. The United Kingdom

7.7.1. Total Diagnosed cases of EBV Infectious Mononucleosis in the UK

7.7.2. Total Incident cases of EBV+ Cancers in the UK

7.7.3. Total Incident cases of EBV+ PTLD in the UK

7.8. Japan

7.8.1. Total Diagnosed cases of EBV Infectious Mononucleosis in Japan

7.8.2. Total Incident cases of EBV+ Cancers in Japan

7.8.3. Total Incident cases of EBV+ PTLD in Japan

8. Unmet Needs

9. Bibliography

10. Appendix

10.1. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Table

Table 1: Prevalence of signs, symptoms, and laboratory abnormalities in infectious mononucleosis

Table 2: Complications reported in ≥1% of cases of infectious mononucleosis

Table 3: Biological activities of Epstein Barr virus latency stage gene products

Table 4: Expression of EBV latent genes associated with latency programs

Table 5: EBV associated diseases

Table6: Epstein-Barr virus-positive versus Epstein-Barr virus-negative PTLD

Table 7: Early versus late-onset PTLD in adults

Table 8: Serological profiles in Epstein–Barr virus reactivation and Epstein–Barr virus-associated diseases

Table 9: Interpretation of Epstein–Barr virus serological profiles in immunocompetent patients

Table 10: Interpretation of IgG avidity test with immunoblotting

Table 11: Advantages and Disadvantages of various EBV diagnostic methods

Table 12: Differential Diagnosis

Table 13: Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM (2017–2030)

Table 14: Total Incident Population of EBV+ Cancers and PTLD in 7MM

Table 15: Major Sources used to derive cancer and transplantation cases

Table 16: Total Diagnosed Cases of EBV Infectious Mononucleosis in the US (2017-2030)

Table 17: Total Incident Cases of EBV+ Cancers in the US (2017-2030)

Table 18: Total Incident Cases of EBV+ PTLD in the US (2017-2030)

Table 19: Total Diagnosed Cases of EBV Infectious Mononucleosis in Germany (2017-2030)

Table 20: Total Incident Cases of EBV+ Cancers in Germany (2017-2030)

Table 21: Total Incident Cases of EBV+ PTLD in Germany (2017-2030)

Table 22: Total Diagnosed Cases of EBV Infectious Mononucleosis in France (2017-2030)

Table 23: Total Incident Cases of EBV+ Cancers in France (2017-2030)

Table 24: Total Incident Cases of EBV+ PTLD in France (2017-2030)

Table 25: Total Diagnosed Cases of EBV Infectious Mononucleosis in Italy (2017-2030)

Table 26: Total Incident Cases of EBV+ Cancers in Italy (2017-2030)

Table 27: Total Incident Cases of EBV+ PTLD in Italy (2017-2030)

Table 28: Total Diagnosed Cases of EBV Infectious Mononucleosis in Spain (2017-2030)

Table 29: Total Incident Cases of EBV+ Cancers in Spain (2017-2030)

Table 30: Total Incident Cases of EBV+ PTLD in Spain (2017-2030)

Table 31: Total Diagnosed Cases of EBV Infectious Mononucleosis in the UK (2017-2030)

Table 32: Total Incident Cases of EBV+ Cancers in the UK (2017-2030)

Table 33: Total Incident Cases of EBV+ PTLD in the UK (2017-2030)

Table 34: Total Diagnosed Cases of EBV Infectious Mononucleosis in Japan (2017-2030)

Table 35: Total Incident Cases of EBV+ Cancers in Japan (2017-2030)

Table 36: Total Incident Cases of EBV+ PTLD in Japan (2017-2030)

List of Figures

Figure 1: Classification of the EBV virus

Figure 2: Symptoms of Infectious Mononucleosis

Figure 3: Risk factors associated with EBV infection

Figure 4:  Cell transformation and cell proliferation of tumor cell lines in EBV-cancers

Figure 5: The Epstein–Barr virus genome

Figure 6: Putative in vivo interactions between Epstein–Barr virus and host cells

Figure 7: Activities of Selected EBV Proteins

Figure 8: Total Diagnosed Cases of EBV+ Infectious Mononucleosis in 7MM (2017–2030)

Figure 9: Total Incident Population of EBV+ Cancers and PTLD in 7MM (2017–2030)

Figure 10: Global burden of EBV-attributable malignancies- 2017

Figure 11: Total Diagnosed Cases of EBV Infectious Mononucleosis in the US (2017-2030)

Figure 12: Total Incident Cases of EBV+ Cancer in the US (2017-2030)

Figure 13: Total Incident Cases of EBV+ PTLD in the US (2017-2030)

Figure 14: Total Diagnosed Cases of EBV Infectious Mononucleosis in Germany (2017-2030)

Figure 15: Total Incident Cases of EBV+ Cancer in Germany (2017-2030)

Figure 16: Total Incident Cases of EBV+ PTLD in Germany (2017-2030)

Figure 17: Total Diagnosed Cases of EBV Infectious Mononucleosis in France (2017-2030)

Figure 18: Total Incident Cases of EBV+ Cancer in France (2017-2030)

Figure 19: Total Incident Cases of EBV+ PTLD in France (2017-2030)

Figure 20: Total Diagnosed Cases of EBV Infectious Mononucleosis in Italy (2017-2030)

Figure 21: Total Incident Cases of EBV+ Cancer in Italy (2017-2030)

Figure 22: Total Incident Cases of EBV+ PTLD in Italy (2017-2030)

Figure 23: Total Diagnosed Cases of EBV Infectious Mononucleosis in Spain (2017-2030)

Figure 24: Total Incident Cases of EBV+ Cancer in Spain (2017-2030)

Figure 25: Total Incident Cases of EBV+ PTLD in Spain (2017-2030)

Figure 26: Total Diagnosed Cases of EBV Infectious Mononucleosis in the UK (2017-2030)

Figure 27: Total Incident Cases of EBV+ cancer in the UK (2017-2030)

Figure 28: Total Incident Cases of EBV+ PTLD in the UK (2017-2030)

Figure 29: Total Diagnosed Cases of EBV Infectious Mononucleosis in Japan (2017-2030)

Figure 30: Total Incident Cases of EBV+ Cancer in Japan (2017-2030)

Figure 31: Total Incident Cases of EBV+ PTLD in Japan (2017-2030)

Figure 32: Treatment of IM

Figure 33: Algorithm for management and treatment of PTLD

Figure 34: Treatment algorithm of PTLD

Figure 35: Prevention of EBV infection

Figure 36: Unmet Needs

  • Tags:
  • Epstein Barr virus (EBV) Epidemiol...
  • Epstein Barr virus (EBV)
  • Epstein Barr virus (EBV) Pipeline
  • Epstein Barr virus (EBV) Companie...
  • Epstein Barr virus (EBV) prevalen...
  • Epstein Barr virus (EBV) incident...
  • Epstein Barr virus (EBV) patients...
  • Epstein Barr virus (EBV) treatmen...

Forward to Friend

Need A Quote